Xiao, Jingfang
Gong, Xiaoyuan
Fu, Zhenlan
Song, Xiongbo
Ma, Qinghua
Miao, Jingya
Cai, Ruili
Yan, Zexuan
Wang, Shuai
Li, Qian
Chen, Yaokai
Yang, Liu
Bian, Xiuwu
Chen, Yemiao http://orcid.org/0000-0001-5397-1407
Funding for this research was provided by:
Chongqing Science and Technology Commission (CSTB2022TIAD-KPX0158)
Jiangsu Association for Science and Technology (TC2022B009)
Article History
Received: 18 April 2023
Accepted: 10 October 2023
First Online: 19 November 2023
Declarations
:
: The harvesting of ADSCs from humans was conducted in accordance with the precepts of Declaration of Helsinki and was approved by the Ethics Committee of the First Affiliated Hospital of Army Medical University (Approval Number: KY2020044) on the March 30th, 2020. The approved title is: Characterization of fat pad mesenchymal stem cells and perivascular cells, and their combination with nano-medicines in anti-tumor. This ethics approval comprises two parts. The first part is the influence of inflammation on the characteristics of ADMSCs (the present article), and the second part is related to an anti-tumor study of ADMSCs combined with nano-medicines. All sample donors have signed informed consent forms. For underage sample donors, both the individual and their legal guardian have jointly signed the informed consent forms in accordance with the process approved by the ethics committee. Animal study was conducted in accordance with the Basel Declaration of 2010 and was approved by the Laboratory Animal Welfare and Ethics Committee of Army Medical University under protocol no. 20210029. Protocol title: Targeted nano-delivery system based on mesenchymal stem cells. Approval date: February 24th, 2021.
: Not applicable.
: The authors declare that they have no conflict of interest.